Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

European Urology

Volumn 62, Issue 6, 2012, Pages 966-972

  Lu Yao, Grace L ^a,b,c   Albertsen, Peter C ^d   Li, Hui ^b   Moore, Dirk F ^c,e   Shih, Weichung ^c,e   Lin, Yong ^c,e   Dipaola, Robert S ^a,b,c   Yao, Siu Long ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c Betty Gallo Prostate Cancer Center   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Antineoplastic agents hormonal; Medicare; Prostatic neoplasm; SEER program

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER NECK STENOSIS; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; CYSTOTOMY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEPHROSTOMY; POPULATION RESEARCH; PRIMARY ANDROGEN DEPRIVATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SPINAL CORD COMPRESSION; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COHORT STUDIES; HUMANS; MALE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 84868571745     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.003     Document Type: Article

References (30)

1. Y.H. Shao, K. Demissie, and W. Shih Contemporary risk profile of prostate cancer in the United States J Natl Cancer Inst 101 2009 1280 1283
2. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181
3. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
4. F.H. Schröder, K.H. Kurth, and S.D. Fosså Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study J Urol 172 2004 923 927
5. Y.N. Wong, S.J. Freedland, B. Egleston, N. Vapiwala, R. Uzzo, and K. Armstrong The role of primary androgen deprivation therapy in localized prostate cancer Eur Urol 56 2009 609 616
6. D.G. McLeod, P. Iversen, W.A. See, T. Morris, J. Armstrong, M.P. Wirth Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
7. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
8. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603
9. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
10. A.L. Potosky, B.B. Reeve, and L.X. Clegg Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy J Natl Cancer Inst 94 2002 430 437
11. N. Sadetsky, K. Greene, M.R. Cooperberg, A. Hubbard, P.R. Carroll, and W. Satariano Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry Cancer 117 2011 4406 4413
12. J.L. Warren, C.N. Klabunde, D. Schrag, P.B. Bach, and G.F. Riley Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 Suppl 8 2002 IV-3-18
13. J.L. Warren, L.C. Harlan, and A. Fahey Utility of the SEER-Medicare data to identify chemotherapy use Med Care 40 Suppl 8 2002 IV-55-61
14. C.N. Klabunde, A.L. Potosky, J.M. Legler, and J.L. Warren Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267
15. T.A. Stukel, E.S. Fisher, D.E. Wennberg, D.A. Alter, D.J. Gottlieb, and M.J. Vermeulen Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods JAMA 297 2007 278 285
16. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, E. Orihuela, and J.S. Goodwin Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615 1624
17. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist J Natl Cancer Inst 98 2006 839 845
18. J. Angrist, G. Imbens, and D. Rubin Identification of causal effects using instrumental variables J Am Stat Assoc 91 1996 444 455
19. T.M. Therneau, and P.M. Grambsch Modeling survival data: extending the Cox model 2000 Springer New York, NY
20. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
21. Y. Sun, B.-E. Wang, and K.G. Leong Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy Cancer Res 72 2012 527
22. K. Jennbacken, T. Tesan, W. Wang, H. Gustavsson, J.E. Damber, and K. Welen N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer Endocr-Related Cancer 17 2010 469 479
23. P. Koivisto, J. Kononen, and C. Palmberg Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 57 1997 314 319
24. P.A. Koivisto, and H.J. Helin Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma J Pathol 189 1999 219 223
25. C. Kaltz-Wittmer, U. Klenk, and A. Glaessgen FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy Lab Inves 80 2000 1455 1464
26. Y.A.N. Shi, F.H. Brands, and S. Chatterjee HER-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease J Urol 166 2001 1514 1519
27. C. Ricciardelli, M.W. Jackson, and C.S. Choong Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential Prostate 68 2008 830 838
28. B.Y. Bao, J.B. Pao, and C.N. Huang Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy Clin Cancer Res 17 2011 928 936
29. U.E. Studer, L. Collette, and P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949
30. J. Kawakami, J.E. Cowan, E.P. Elkin, D.M. Latini, J. Duchane, and P.R. Carroll Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Cancer 106 2006 1708 1714